<DOC>
	<DOC>NCT01645800</DOC>
	<brief_summary>The aim of this study is to assess the effectiveness in preventing exacerbation of 52 weeks lysozyme administration in patients with COPD.</brief_summary>
	<brief_title>Effects of Lysozyme on Acute Exacerbation of Chronic Obstructive Pulmonary Disease : A Randomised Placebo-Controlled Study</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases, Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
	<mesh_term>Muramidase</mesh_term>
	<criteria>Inclusion criteria; Patients were eligible for inclusion in the study if they were over 20 years of age and below 85 years of age, and had a smoking history, a diagnosis of COPD, a ratio of FEV1 to forced vital capacity(FVC) of less than 70%, and a documented history of at least one exacerbation leading to any treatment within the previous year. Exclusion criteria; Patients with egg allergy Patients with domiciliary oxygen therapy Patients with pneumonia or pulmonary tuberculosis Patients with severe cardiovascular disorder,severe kidney disorder, severe hepatic disorder, severe hematological disorder. Patients with cancer.</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>84 Years</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>Lysozyme hydrochloride</keyword>
	<keyword>COPD</keyword>
</DOC>